Ticiana Leal, MD

One star
One star
One star
One star
One half star

Rating: 4.8 out of 5 (147 ratings)

Role

Medical Oncology
Specialty

Lung Cancer
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2009

Call 404-778-1900

Background

Ticiana Leal, MD is associate professor and serves as director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Board certified in medical oncology and palliative care, Dr. Leal specializes in caring for patients with lung cancer, mesothelioma and thymic malignancies at Winship Cancer Institute.

Before joining Emory, Dr. Leal was a member of the faculty at UW Carbone Cancer Center in Madison, Wisconsin, where she served as team leader of the Thoracic Malignancies Disease Oriented Team.

Dr. Leal received her medical degree from Federal University of Ceara in Fortaleza, Brazil. She completed her residency in internal medicine at Weiss Memorial Hospital in Chicago, Illinois. She completed a fellowship in geriatric medicine at the University of Illinois at Chicago, and a fellowship in medical oncology at the University of Wisconsin Hospitals and Clinics in Madison, Wisconsin.

Dr. Leal's clinical research focuses on clinical trials of chemotherapy and/or immunotherapy agents to treat cancers of the lung.

Dr. Leal has authored or coauthored numerous peer-reviewed original research articles, book chapters and posters. She serves as associate editor and as a member of the executive editorial board of The Journal of the National Comprehensive Cancer Network. She also serves as Lung Cancer Section Editor of Current Treatment Options in Oncology and on the editorial advisory boards of Cancer and The Brazilian Journal of Oncology.

PubMed

Titles & Roles

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Medical Director, Clinical Trials Office

Winship Cancer Institute of Emory University
Leader, Lung Cancer Disease Team

Winship Cancer Institute of Emory University
Director, Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology

Emory University School of Medicine

Education & Training

Education

Fellowship, Medical Oncology, 2009
University of Wisconsin
Fellowship, Geriatric Medicine, 2007
University of Illinois at Chicago
Residency, Internal Medicine, 2006
Weiss Memorial Hospital
Medical Education, MD, 2001
Federal University of Ceara

Professional Memberships

Dr. Leal holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, Eastern Cooperative Oncology Group, European Society of Medical Oncology, Society for Immunotherapy of Cancer, and International Association for the Study of Lung Cancer. She is the NCI LUNG-MAP Chair, ECOG-ACRIN representative.

Research

View Current Clinical Trials


A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase II Conditions Carcinoma, Non-Small-Cell Lung Location Emory University Hospital Midtown, Winship Cancer Institute
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) Phase I/II Conditions Locally Advanced Solid Tumor, Metastatic Solid Tumor Location Winship Cancer Institute
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) Phase III Conditions Non Small Cell Lung Cancer Location Emory University Hospital Midtown, Winship Cancer Institute
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab Phase III Conditions Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer Location Winship Cancer Institute
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS Phase III Conditions Carcinoma, Non-Small-Cell Lung Location Winship Cancer Institute
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies Phase I Conditions Advanced Cancer Location Winship Cancer Institute
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) Phase I Conditions Neoplasm Metastasis, Non-Small Cell Lung Cancer Location Emory University Hospital Midtown, Winship Cancer Institute
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer Phase III Conditions Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis Location Emory University Hospital Midtown, Winship Cancer Institute
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer Phase I Conditions Small Cell Lung Carcinoma (SCLC) Location Emory University Hospital Midtown, Winship Cancer Institute
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors Phase I Conditions Cancer Location Winship Cancer Institute
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) Phase I/II Conditions Locally Advanced Solid Tumor, Metastatic Solid Tumor Location Winship Cancer Institute
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Phase I Conditions NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer Location Winship Cancer Institute
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation Phase I Conditions Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation Location Winship Cancer Institute
STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors Phase I Conditions Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency Location Winship Cancer Institute
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial Phase II Conditions Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm Location Winship Cancer Institute
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) Phase I Conditions Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation Location Emory University Hospital Midtown, Winship Cancer Institute
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer Phase III Conditions Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 Location Emory University Hospital Midtown, Winship Cancer Institute
Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer Phase I Conditions Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC V8 Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change Phase II Conditions Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7 Location Emory University Hospital Midtown, Winship Cancer Institute

Publications

Title/Journal	Authors	Publication Date
Maxing out with chemoimmunotherapy in extensive-stage small cell lung cancer. Chinese clinical oncology	K Canaslan, L Xiao, T Leal	04/01/2025
Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer. Future oncology (London, England)	JP Higgins, JW Carlisle, NH Moniri, S Gupta, EI Oduah, T Leal	01/01/2025
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	AH Nassar, R Jayakrishnan, J Feng, F Shepherd, E Adib, JM Cheung, JJ Lin, Y Liu, SH Lin, K Parikh, A Sridhar, P Shakya, TJ Dilling, D Kaldas, JE Gray, A Lobachov, J Bar, H Luders, C Grohe, S Gupta, T Leal, B Fitzgerald, F Crowley, Y Fujiwara, TU Marron, M Wilgucki, J Reuss, L Chen, K Sankar, JV Aredo, JW Neal, HA Wakelee, R Thummalapalli, H Yu, R Whitaker, A Velazquez, M Ragavan, A Cortellini, DJ Kwiatkowski, AR Naqash, SB Goldberg, SY Kim	01/01/2025
Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981. iScience	R Sharma, S Sharma, P Shriwas, L Mehta, AH Vu, JK Mouw, J Koo, C Huang, VY Matsuk, C Tucker-Burden, G Joseph, M Behera, SY Sun, MA Roy, M Gilbert-Ross, T Leal, AI Marcus, M Shanmugam	11/15/2024
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer. The Journal of experimental medicine	Z Chen, KA Vallega, D Wang, Z Quan, S Fan, Q Wang, T Leal, SS Ramalingam, SY Sun	11/04/2024
Real-World Outcomes of First-Line Treatment With Anti-PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States. JCO global oncology	SV Liu, A Dasgupta, D Latremouille-Viau, C Rossi, P Rai, F Barlesi, TA Leal	09/01/2024
Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	J Carlisle, Y Liu, T Leal	07/10/2024
Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best. Cancer	TA Leal, SS Ramalingam	06/01/2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	AH Nassar, SY Kim, JV Aredo, J Feng, F Shepherd, C Xu, D Kaldas, JE Gray, TJ Dilling, JW Neal, HA Wakelee, Y Liu, SH Lin, T Abuali, A Amini, Y Nie, T Patil, A Lobachov, J Bar, B Fitzgerald, Y Fujiwara, TU Marron, R Thummalapalli, H Yu, DH Owen, J Sharp, S Farid, P Rocha, E Arriola, A D'Aiello, H Cheng, R Whitaker, K Parikh, Y Ashara, L Chen, K Sankar, JP Harris, M Nagasaka, A Ayanambakkam, AI Velazquez, M Ragavan, JJ Lin, Z Piotrowska, M Wilgucki, J Reuss, H Luders, C Grohe, J Baena Espinar, E Feiner, SR Punekar, S Gupta, T Leal, DJ Kwiatkowski, RH Mak, E Adib, AR Naqash, SB Goldberg	06/01/2024
Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial. International journal of radiation oncology, biology, physics	MF Bassetti, BA Morris, N Sethakorn, JM Lang, JL Schehr, SG Zhao, ZS Morris, D Buehler, JC Eickhoff, PM Harari, AM Traynor, TC Campbell, AM Baschnagel, TA Leal	04/01/2024
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. The Journal of clinical investigation	Z Chen, KA Vallega, D Wang, Z Quan, S Fan, Q Wang, T Leal, SS Ramalingam, SY Sun	03/07/2024
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan. JCO global oncology	TA Leal, A Dasgupta, D Latremouille-Viau, C Rossi, P Rai, F Barlesi, SV Liu	03/01/2024
Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer. Cancer	NS McCall, JR Janopaul-Naylor, HS McGinnis, AH Kesarwala, S Tian, WA Stokes, JW Shelton, CE Steuer, JW Carlisle, TA Leal, SS Ramalingam, JD Bradley, KA Higgins	12/01/2023
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' reply. The Lancet. Oncology	T Leal, C Langer	12/01/2023
Advancing immunotherapy in small cell lung cancer. Cancer	JW Carlisle, T Leal	11/15/2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). JCO precision oncology	R Vaidya, JM Unger, L Qian, K Minichiello, RS Herbst, DR Gandara, JW Neal, TA Leal, JD Patel, KH Dragnev, SN Waqar, MJ Edelman, EV Sigal, SJ Adam, S Malik, CD Blanke, ML LeBlanc, K Kelly, JE Gray, MW Redman	09/01/2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. The Lancet. Oncology	T Leal, R Kotecha, R Ramlau, L Zhang, J Milanowski, M Cobo, J Roubec, L Petruzelka, L Havel, S Kalmadi, J Ward, Z Andric, T Berghmans, DE Gerber, G Kloecker, R Panikkar, J Aerts, A Delmonte, M Pless, R Greil, C Rolfo, W Akerley, M Eaton, M Iqbal, C Langer	09/01/2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	K He, D Berz, SM Gadgeel, WT Iams, DS Bruno, CM Blakely, AI Spira, MR Patel, DM Waterhouse, DA Richards, A Pham, R Jotte, DS Hong, EB Garon, A Traynor, P Olson, L Latven, X Yan, R Shazer, TA Leal	07/01/2023
Spotlight on Small-Cell Lung Cancer and Other Lung Neuroendocrine Neoplasms. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	L Fernandez-Cuesta, A Sexton-Oates, L Bayat, M Foll, SCM Lau, T Leal	05/01/2023
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer. Cancer	LC Villaruz, GR Blumenschein, GA Otterson, TA Leal	05/01/2023
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer. Clinical lung cancer	WT Iams, ML Balbach, S Phillips, A Sacher, C Bestvina, V Velcheti, X Wang, ME Marmarelis, N Sethakorn, T Leal, PE Sackstein, C Kim, MA Robinson, K Mehta, R Hsu, J Nieva, T Patil, DR Camidge	05/01/2023
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029. Cancer	T Salous, NA Shukla, SK Althouse, SM Perkins, M Furqan, T Leal, AM Traynor, LE Feldman, NH Hanna, GA Durm	01/15/2023
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. The New England journal of medicine	R Yaeger, J Weiss, MS Pelster, AI Spira, M Barve, SI Ou, TA Leal, TS Bekaii-Saab, CP Paweletz, GA Heavey, JG Christensen, K Velastegui, T Kheoh, H Der-Torossian, SJ Klempner	01/05/2023
Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy. Expert review of anticancer therapy	T Leal, MA Socinski	01/01/2023
A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782). Cancer medicine	TA Leal, MN Sharifi, N Chan, R Wesolowski, AA Turk, JY Bruce, RM O'Regan, J Eickhoff, LM Barroilhet, J Malhotra, J Mehnert, E Girda, E Wiley, N Schmitz, S Andrews, G Liu, KB Wisinski	11/01/2022
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. Clinical lung cancer	BE Osta, J Carlisle, C Steuer, S Pakkala, T Leal, M Dhodapkar, Y Liu, Z Chen, T Owonikoko, S Ramalingam	11/01/2022
A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139. Clinical lung cancer	F Ardeshir-Larijani, SK Althouse, T Leal, LE Feldman, TA Hejleh, M Patel, RD Gentzler, AR Miller, NH Hanna	11/01/2022
Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	NS McCall, HS McGinnis, JR Janopaul-Naylor, AH Kesarwala, S Tian, WA Stokes, JW Shelton, CE Steuer, JW Carlisle, T Leal, SS Ramalingam, JD Bradley, KA Higgins	09/01/2022
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^G12C Solid Tumors (KRYSTAL-1). Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SI Ou, PA Jänne, TA Leal, II Rybkin, JK Sabari, MA Barve, L Bazhenova, ML Johnson, KL Velastegui, C Cilliers, JG Christensen, X Yan, RC Chao, KP Papadopoulos	08/10/2022
Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	TA Leal, SE Dahlberg, SS Ramalingam	07/20/2022
Neoadjuvant therapy gains FDA approval in non-small cell lung cancer. Cell reports. Medicine	TA Leal, SS Ramalingam	07/19/2022
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nature medicine	ES Kim, V Velcheti, T Mekhail, C Yun, SM Shagan, S Hu, YK Chae, TA Leal, JE Dowell, ML Tsai, CSR Dakhil, P Stella, Y Jin, DS Shames, E Schleifman, DA Fabrizio, S Phan, MA Socinski	05/01/2022
Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer. Biomarker research	JL Schehr, N Sethakorn, ZD Schultz, CI Hernandez, RM Bade, D Eyzaguirre, A Singh, DJ Niles, L Henderson, JW Warrick, SM Berry, KE Sundling, DJ Beebe, TA Leal, JM Lang	04/25/2022
Corrigendum: Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound. Frontiers in rehabilitation sciences	J Lortie, B Rush, K Osterbauer, TJ Colgan, D Tamada, S Garlapati, TC Campbell, A Traynor, T Leal, V Patel, JJ Helgager, K Lee, SB Reeder, AJ Kuchnia	01/01/2022
Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound. Frontiers in rehabilitation sciences	J Lortie, B Rush, K Osterbauer, TJ Colgan, D Tamada, S Garlapati, TC Campbell, A Traynor, T Leal, V Patel, JJ Helgager, K Lee, SB Reeder, AJ Kuchnia	01/01/2022
ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts. Molecular cancer therapeutics	AM Baschnagel, JH Elnaggar, HJ VanBeek, AC Kromke, JH Skiba, S Kaushik, L Abel, PA Clark, CA Longhurst, KP Nickel, TA Leal, SG Zhao, RJ Kimple	11/01/2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	J Malhotra, P Nikolinakos, T Leal, J Lehman, D Morgensztern, JD Patel, JM Wrangle, G Curigliano, L Greillier, ML Johnson, N Ready, G Robinet, S Lally, D Maag, R Valenzuela, V Blot, B Besse	09/01/2021
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, M Gottfried, N Peled, A Tafreshi, S Cuffe, M O'Brien, S Rao, K Hotta, TA Leal, JW Riess, E Jensen, B Zhao, MC Pietanza, JR Brahmer	07/20/2021
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	M Boyer, MAN Şendur, D Rodríguez-Abreu, K Park, DH Lee, I Çiçin, PF Yumuk, FJ Orlandi, TA Leal, O Molinier, N Soparattanapaisarn, A Langleben, R Califano, B Medgyasszay, TC Hsia, GA Otterson, L Xu, B Piperdi, A Samkari, M Reck	07/20/2021
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network : JNCCN	DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, DS Bruno, JY Chang, LR Chirieac, TA D'Amico, TJ Dilling, J Dowell, S Gettinger, MA Gubens, A Hegde, M Hennon, RP Lackner, M Lanuti, TA Leal, J Lin, BW Loo, CM Lovly, RG Martins, E Massarelli, D Morgensztern, T Ng, GA Otterson, SP Patel, GJ Riely, SE Schild, TA Shapiro, AP Singh, J Stevenson, A Tam, J Yanagawa, SC Yang, KM Gregory, M Hughes	03/02/2021
Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases. Clinical lung cancer	TL Enright, JS Witt, AR Burr, P Yadav, T Leal, AM Baschnagel	03/01/2021
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SV Liu, M Reck, AS Mansfield, T Mok, A Scherpereel, N Reinmuth, MC Garassino, J De Castro Carpeno, R Califano, M Nishio, F Orlandi, J Alatorre-Alexander, T Leal, Y Cheng, JS Lee, S Lam, M McCleland, Y Deng, S Phan, L Horn	02/20/2021
Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases. Scientific reports	AM Baschnagel, S Kaushik, A Durmaz, S Goldstein, IM Ong, L Abel, PA Clark, Z Gurel, T Leal, D Buehler, G Iyer, JG Scott, RJ Kimple	01/28/2021

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.8	One star One star One star One star One half star	Provider showed concern
4.8	One star One star One star One star One half star	Provider explained things clearly
4.8	One star One star One star One star One half star	Provider discussed treatment options
4.8	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	04/25/2025	We love you Dr. Leal! Thank God for guiding you in caring for your patients.You are priceless!
One star One star One star One star One star	03/29/2025	We love Dr. Leal!She is compassionate about your health and care that you will get back to your normal life.She is priceless ! We love her!
One star One star One star One star One star	03/28/2025	Had great phone chat with Dr. Leal!!
One star One star One star One star One star	03/25/2025	Process broke down with scheduling follow up needs. Unclear of failure point.
One star One star One star One star One star	03/21/2025	Had a great visit with Dr. Leal!!
One star One star One star One star One star	02/15/2025	I cannot be more pleased with Dr. Leal's preparation for my visit by reviewing the data submitted on prior care. She is an excellent listener, very patient in responding to questions from both myself and my family, and her recommendations were of great assistance to me.
One star One star One star One star One star	02/14/2025	Good
One star One star One star One star One star	02/14/2025	Made me very comfortable
One star One star One star One star One star	02/13/2025	My Dr., Dr.Leal, was working me in for my appointments. So any delay which was very little, was understood and she still took her time with me
One star One star One star One star One star	01/17/2025	I am so grateful to have Dr. Leal as my doctor. She always has time to talk to me and answer my questions
One star One star One star One star One star	01/10/2025	Dr. Leal, You Rock! We are so blessed to have you as our Lung Oncologist! Your healing is impeccable and compassionate! Priceless!Thank you! We love you
One star One star One star One star One star	12/19/2024	Nobody better than Dr. Leal, Cortney and the rest rest of there staff including office secretaries who take a send messages.
One star One star One star One star One star	12/06/2024	We love Dr. Leal! Awesome! Awesome!Compassionate! Loving! Caring! Focus on the solution for getting better.
One star One star One star One star One star	12/05/2024	Dr. Leal is a kind caring doctor. She listens to me and we discuss my concerns
One star One star One star One star One star	11/21/2024	Dr Leal was pleased with reports,Checked my arms and legs and prescribed med. Very thorough.
One star One star One star One star One star	10/19/2024	Dr Leal is excellent and very caring
One star One star One star One star One star	09/28/2024	Dr. Leal is absolutely the best doctor I have seen. First, she listens carefully what I told her, and answer all questions I had. Secondly, she is so experienced expert who can answers all my questions and gives reasonable suggestions. Thirdly, she always gives me good a future treatment plan after discussing it with me. Finally, she shows me the most recent information on published researches when she discusses the treatment plan, indicating she is keeping learning the most recent developments in the field.
One star One star One star One star One star	09/26/2024	Dr. Leal was extremely knowledgeable, kind and direct. Appreciate her.
One star One star One star One star One star	09/25/2024	Dr Leal has shown that she cares about me from the start. I've now been her patient for over a year and continue to receive very good care. She figured out the right Immunotherapies that have succeeded in removing my cancer. I was stage 4 with a death sentence. With the help of God and Dr. Leal, I'm now cancer free.
One star One star One star One star One star	09/21/2024	Dr. Leal is Best of Class !
One star One star One star One star One star	08/16/2024	Dr. Leal is Awesome! She has great listening skills, she shows great compassion for my needs and want me to recover from my Lung cancer her approach to working with me through the process and giving high quality improvement to my health. Thank you Dr. Leal
One star One star One star One star One star	08/15/2024	Dr Leal is extraordinary doctor caring and veyKnowledgeable. I am very happy for her care.
One star One star One star One star One star	07/04/2024	Dr Leal was fantastic. She explained everything and never rushed me.
One star One star One star One star One star	07/04/2024	Dr. Leal is an excellent doctor. She took the time to listen and very clearly explain the benefits and risks of treatment for my dad. She is very knowledgeable and answered all of our questions. I'm grateful she is my dad's doctor, I feel he is in great hands with her.
One star Empty star Empty star Empty star Empty star	07/03/2024	Terrible bed side manner very uncaring and zero professionalism
One star One star One star One star One star	06/28/2024	Showed compassion and ready to help get us back to full health
One star One star One star One star One star	06/21/2024	Dr Leal is engaged and thorough.
One star One star One star One star One star	05/30/2024	Good visit.